First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

British Journal of Cancer 116, 1126 (25 April 2017). doi:10.1038/bjc.2017.62

Authors: Eric Angevin, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Philippe Vielh, Françoise Farace, Fanny Valleix, Thomas Podoll, Yu Kuramochi, Itaru Miyashita, Osamu Hosono, Nam H Dang, Kei Ohnuma, Taketo Yamada, Yutaro Kaneko & Chikao Morimoto

from Cancer via ola Kala on Inoreader http://ift.tt/2mqe6uB
via IFTTT